INTRODUCTION
============

The *O*-GlcNAc (O-linked *N*-acetylglucosamine) modification is a dynamic and reversible form of protein glycosylation occurring on specific serine and threonine residues of intracellular proteins \[[@B1],[@B2]\]. Since the initial discovery of *O*-GlcNAc \[[@B3]\], technological advances have greatly facilitated its detection, and proteomics studies \[[@B4]--[@B6]\] have shown that a significant proportion of cellular proteins are *O*-GlcNAcylated. However, the functional importance of *O*-GlcNAc is only just emerging, with evidence to suggest that it may regulate protein activity in a manner analogous (and complementary) to phosphorylation \[[@B7]\]. *O*-GlcNAc levels are known to respond dynamically to nutrient availability \[[@B1]\] and stress \[[@B8]\], and to undergo changes during the cell cycle \[[@B9]\] and development \[[@B10]\]. *O*-GlcNAc has been shown to be associated with a range of human diseases \[[@B2]\]. Strikingly, only two enzymes orchestrate the *O*-GlcNAc modification. Both the OGT (*O*-GlcNAc transferase) and its antagonistic OGA (*O*-GlcNAcase or β-N-acetylglucosaminidase) are encoded by single genes in metazoa \[[@B11],[@B12]\]. Little is known about the mode of substrate recognition of either enzyme, although studies have hinted at the existence of a defined *O*-GlcNAc peptide sequon \[[@B2],[@B5]\]. In addition, it is thought that, for a single OGT to modify specific sites on a multitude of proteins, interactions with adapter proteins may be instrumental in achieving selectivity and regulation of activity \[[@B13]\].

OGA was first identified as a neutral-pH hexosaminidase, which was later associated with the gene *MGEA5* (meningioma-expressed antigen 5) \[[@B14]\]. The domain structure of hOGA (human OGA) is frequently oversimplified by designating an N-terminal hexosaminidase followed by a C-terminal domain with sequence homology with HATs (histone acetyltransferases) (referred to as the HAT domain in the present paper). A further putative domain may exist in the stretch of over 300 amino acids in between the hexosaminidase and HAT domains. hOGA (Ser^405^) is itself a substrate for OGT \[[@B15]\]. Residues 404--548 have been shown to be required for interaction with OGT \[[@B16]\], and it is thought that the formation of such a complex negatively regulates *O*-GlcNAc removal.

Pharmacological inhibition of OGA has been an invaluable tool for investigating the cellular functions of *O*-GlcNAc; notably the non-selective inhibitor PUGNAc \[*O*-(2-acetamido-2-deoxy-[D]{.smallcaps}-glucopyranosylidene)amino-*N*-phenylcarbamate\] has been used extensively to raise cellular *O*-GlcNAc levels \[[@B17]\]. Advances in understanding of the OGA reaction mechanism \[[@B18]\], in conjunction with structures of bacterial OGAs \[[@B19],[@B20]\], have informed the development of a number of highly potent and selective inhibitors for hOGA \[[@B21]\].

Despite these recent advances in our understanding of OGA structure, mechanism and inhibition, we do not understand how OGA interacts with the protein part of its substrates. Such interactions could constitute the basis of substrate specificity in hOGA. In the present paper, we reveal that hOGA possesses a conserved substrate-binding groove that is required for the interaction with *O*-GlcNAc proteins. Different substrates require distinct surface residues for binding, affording a first glimpse into the substrate selectivity of human *O*-GlcNAcase.

MATERIALS AND METHODS
=====================

Cloning, expression and structure determination of *Og*OGA (*Oceanicola granulosus* OGA)
----------------------------------------------------------------------------------------

The *O. granulosus* gene for hyaluronoglucosaminidase (ZP_01156836.1) was cloned from genomic DNA into pGEX6-P1 for expression as a GST (glutathione transferase) fusion in *Escherichia coli*. The protein *Og*OGA was purified by affinity, anion-exchange and size-exclusion chromatography (see the Supplementary material at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>). *Og*OGA was crystallized at 1.9 mg/ml from PEG \[poly(ethylene glycol)\]/MgCl~2~ solutions (see the Supplementary Online Data). The structure of the apo-enzyme was solved using MAD (multiwavelength anomalous diffraction) phasing with a lead derivative and the structure of a PUGNAc complex was obtained by molecular replacement. Diffraction data and model statistics are shown in Supplementary Table S1 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>.

Glycopeptide synthesis and detection
------------------------------------

A 3,4,6-triacetyl-*O*-GlcNAc-Fmoc (fluoren-9-ylmethoxycarbonyl)-Ser-OH derivative was synthesized as described previously \[[@B22]\]. Microwave-assisted solid-phase peptide synthesis was performed with a CEM Liberty instrument on low-load Rink amide MBHA (methylbenzhydrylamine) resin 100--200 mesh (Novabiochem) using standard Fmoc chemistry protocols on a 0.05 mmol scale. The structural homogeneity of the glycopeptides was verified by high-resolution mass spectra taken on Bruker micro-TOF (time-of-flight) instrument in the direct injection mode. The same instrument was used for the monitoring of the enzymatic deglycosylation in the LC (liquid chromatography)--MS mode using an Agilent 1200 binary analytical HPLC system equipped with a Waters X-Bridge C~18~ 3 μm particles, 3.2 mm×50 mm column and diode array UV--visible detector. Typically, the reaction was diluted to 0.3 ml with water, then passed through a 10 kDa molecular-mass cut-off concentrator to remove protein. Then, 10 μl of the flow-through was taken for the analysis using gradient elution (flow rate 0.3 ml/min) with a 5--95% linear gradient of acetonitrile (0.1% ammonia) in water (0.1% ammonia).

hOGA cloning and expression
---------------------------

The coding sequence for full-length hOGA was cloned into the pEBG-6P vector \[[@B23]\] for transient expression in mammalian cells. Point mutations were introduced by site-directed mutagenesis (see Supplementary Table S2 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm> for primers). The enzyme was expressed as an N-terminal GST fusion in HEK (human embryonic kidney)-293 cells cultivated in suspension. For transfection, 2×10^8^ HEK-293 cells were serum-deprived for 4 h in 100 ml of Pro293sCDM medium before the addition of 10 ml of serum-free medium containing 100 μg of plasmid DNA and 600 μg of polyethylenimine. After another 4 h, the cells were diluted to 10^6^ cells/ml, and the medium was supplemented with 1% (v/v) fetal bovine serum. Cell pellets were harvested 72 h after transfection and lysed in 50 mM Tris/HCl (pH 7.5), 270 mM sucrose, 0.1% 2-mercaptoethanol, 1 mM sodium orthovanadate, 1 mM EDTA, 1 mM EGTA, 5 mM pyrophosphate, 10 mM sodium 2-glycerophosphate, 50 mM NaF, 1% Triton X-100, 1 mM benzamidine, 0.2 mM PMSF and 5 μM leupeptin. GST--hOGA was purified from cleared lysate by pull-down with glutathione--Sepharose (GE Healthcare), followed by elution with 25 mM reduced glutathione in 25 mM Tris/HCl buffer (pH adjusted to 7.5).

Colorimetric and fluorimetric OGA assays
----------------------------------------

Initial rates of hydrolysis of *p*NP-GlcNAc (*p*-nitrophenyl-β-*N*-acetylglucosamine) were measured in buffer containing 25 mM Tris/HCl (pH 7.5) and 0.1 mg/ml BSA, with substrate concentrations ranging from 0 to 10 mM with a DMSO concentration of 2% throughout the assay. Reactions were performed with 5 nM enzyme in a 50 μl assay volume. After 30 min of incubation at 37 °C, the reaction was stopped by addition of 100 μl of 3 M glycine/NaOH (pH 10.3), and product concentration was measured at *A*~405~. 4MU-GlcNAc (4-methylumbelliferyl-β-*N*-acetylglucosamine) assays were performed in the same buffer, with substrate concentrations ranging from 0 to 8 mM, and the enzyme concentration was reduced to 0.2 nM and the assay time to 20 min. Product formation was determined fluorimetrically (λ~ex~=360 nm/λ~em~=460 nm). Inhibition constants for OGA inhibitors were obtained with 4MU-GlcNAc with substrate concentrations equivalent to the *K*~m~. All experiments were performed in triplicate, and results were analysed and plotted using GraphPad Prism.

Kinetic parameters of 4MU-GlcNAc turnover by wild-type and mutant hOGA were determined as described above, with enzyme concentrations of 20 nM and a maximum substrate concentration of 2 mM (1% DMSO in the assay). Competition assays with peptides were performed at 200 μM 4MU-GlcNAc. *K*~m~ determination for GlcNAc-modified peptides was performed following an approach using established equations for multisubstrate enzyme kinetics to derive kinetic constants of a substrate whose turnover cannot be detected directly \[[@B24]\]. The fluorigenic reporter substrate and the GlcNAcylated peptide are considered as competitive inhibitors of each other. From the initial hydrolysis rates of 4MU-GlcNAc in the presence and absence of the peptide, the Michaelis constant for the peptide (*K*~m~′) can be determined from [eqn (1)](#m01){ref-type="disp-formula"}: $$\documentclass[12pt]{minimal}
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Determination of hOGA *in vitro* activity on *O*-GlcNAc proteins
----------------------------------------------------------------

The known *O*-GlcNAc targets FoxO1 (forkhead box O1) \[[@B25],[@B26]\] and CREB (cAMP-response-element-binding protein) \[[@B27]\] were provided by the Division of Signal Transduction and Therapy, University of Dundee, Dundee, Scotland, U.K. Both are truncated constructs and N-terminal GST-fusion proteins, GST--CREB-(1--283), and GST--FoxO1-(329--655). A GST-fusion of the TAB1 (transforming growth factor-β-activated protein kinase 1-binding protein 1) N-terminal domain and full-length hOGT were purified as described elsewhere \[[@B27a]\]. A truncated construct lacking the first nine TPRs (tetratricopeptide repeats) (Δ9-hOGT) was expressed in *E. coli*.

For GlcNAcylation reactions, target proteins were incubated with 3.75 mM UDP-GlcNAc and recombinant OGT in 50 mM Tris/HCl (pH 7.5) containing 1 mM DTT (dithiothreitol). Enzyme/substrate protein ratios were 1:20, total protein concentration was 0.5 mg/ml. The reaction was allowed to proceed for 3 h at 37 °C (see Supplementary Figure S1 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>). Full-length hOGT was used to O-GlcNAcylate CREB and hOGA, whereas the truncated Δ9-hOGT was used for FoxO1 and TAB1. After the glycosylation reaction, target proteins were repurified by GST pull-down, eluted in 25 mM Tris/HCl buffer (pH 7.5) containing 25 mM reduced glutathione and spin-concentrated to approx. 5 mg/ml.

*In vitro* removal of *O*-GlcNAc was performed in a 5 μl volume in 25 mM Tris/HCl and 25 mM GST (pH 7.5), and contained 10 μM O-GlcNAcylated substrate protein and 1 μM wild-type or mutant hOGA. Reaction mixtures were incubated for 4--6 h at 37 °C, and a 1 μl aliquot was blotted for *O*-GlcNAc with CTD110.6 (Abcam). DM-17 rabbit anti-hOGT antibody was purchased from Sigma. GST and TAB1 antisera were obtained from the Division of Signal Transduction and Therapy \[[@B28]\].

RESULTS AND DISCUSSION
======================

Recombinant hOGA is active on *O*-GlcNAc-modified proteins and peptides *in vitro*
----------------------------------------------------------------------------------

Although hOGA has been shown to be active on a GlcNAc-modified peptide substrate \[[@B29]\], most studies have been restricted to measuring the enzyme activity *in vitro* using pseudosubstrates, or monitoring OGA activity *in vivo* by Western blot analysis of cellular *O*-GlcNAc levels after overexpression, knock down or inhibition of OGA. We aimed to demonstrate *in vitro* activity of hOGA on recombinant glycoproteins. Substrates were prepared by *in vitro* glycosylation of the previously characterized *O*-GlcNAc proteins TAB1 and the transcription factors FoxO1 and CREB (see Supplementary Figure S1). OGA assays were then performed with these substrates as well as a glycosylated hOGA inactive mutant, and reduction of *O*-GlcNAc was detected by anti-*O*-GlcNAc Western blot analysis, showing that hOGA is capable of removing *O*-GlcNAc from these glycoproteins ([Figure 1](#F1){ref-type="fig"}A). We next sought to identify peptide substrates that would allow the determination of the Michaelis constant (*K*~m~), and also allow for varying sequence and length to probe substrate specificity. Peptides covered the *O*-GlcNAc sites on TAB1 (Ser^395^) (S. Pathak and D.M.F. van Aalten, unpublished work) and hOGA (Ser^405^) \[[@B4]\] ([Table 1](#T1){ref-type="table"}). hOGA activity on these peptides was confirmed by LC--MS. The affinity of hOGA for these peptides was then quantified by their ability to compete with the reporter substrate 4MU-GlcNAc ([Figure 1](#F1){ref-type="fig"}B and [Table 1](#T1){ref-type="table"}). The resulting *K*~m~ values for the hOGA-Ser^405^- and TAB1-Ser^395^-derived peptides are in the high-micromolar and low-millimolar range respectively, somewhat decreasing in affinity with increasing peptide length.

![Activity of hOGA and *Og*OGA\
(**A**) The *O*-GlcNAc substrate proteins (10 μM) TAB1, FoxO1 and were subjected to *in vitro* GlcNAcylation by recombinant OGT (see Supplementary Figure S1 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>). For the activity assay, these substrates, as well as GlcNAc-modified hOGA D175N, were incubated with hOGA (1 μM) at 37 °C, which led to complete deglycosylation within 6 h as detected by anti-*O*-GlcNAc antibody. The top panel shows the enzyme hOGA as detected through its GST tag, the middle panel shows *O*-GlcNAcylation using CTD110.6 anti-*O*-GlcNAc antibody, and the bottom panel shows all the substrate proteins through their GST tags (shorter exposure). (**B**) Competition of *O*-GlcNAc-modified peptides (tri-, penta-, hepta- and nona-peptides based on the *O*-GlcNAc site on hOGA Ser^405^) with 4MU-GlcNAc turnover by hOGA affords an estimate of the affinity of hOGA for the peptide substrates ([Table 1](#T1){ref-type="table"}). (**C**) Mass spectrum showing the deglycosylation of Val-Ala-His-Ser-(β-*O*-GlcNAc)-Gly-Ala (molecular mass of 785 Da) to the deglycosylated form (molecular mass of 582 Da), also see Supplementary Figure S2 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>.](bic654i001){#F1}

###### Michaelis constants of *O*-GlcNAc-modified peptides for hOGA

*K*~m~ values for peptides derived from the *O*-GlcNAc sites of two known substrate proteins were determined in a competitive assay with the fluorigenic substrate 4MU-GlcNAc. Ac, acetyl; amino acids in peptides are indicated using the single-letter code.

  Substrate                               *K*~m~
  --------------------------------------- ------------
  hOGA-Ser^405^-derived peptide series    
    Ac-HS(-β-*O*-GlcNAc)G-NH~2~           525±13 μM
    Ac-VAHS(-β-*O*-GlcNAc)GA-NH~2~        1204±43 μM
    Ac-VAHS(-β-*O*-GlcNAc)GAK-NH~2~       789±36 μM
    Ac-QVAHS(-β-*O*-GlcNAc)GAKAS-NH~2~    528±15 μM
  TAB1-Ser^395^-derived peptide series:   
    Ac-YS(-β-*O*-GlcNAc)S-NH~2~           2.2±0.1 mM
    Ac-PYS(-β-*O*-GlcNAc)SA-NH~2~         6.3±0.5 mM
    Ac-VPYS(-β-*O*-GlcNAc)SAQ-NH~2~       4.1±0.3 mM
    Ac-SVPYS(-β-*O*-GlcNAc)SAQS-NH~2~     4.8±0.3 mM

Discovery of a bacterial OGA with improved similarity to the human enzyme
-------------------------------------------------------------------------

hOGA is known to possess an N-terminal catalytic domain (residues 60--366) and the C-terminal HAT domain (residues 707--916) ([Figure 2](#F2){ref-type="fig"}A). However, sequence analysis of putative metazoan OGAs shows that they also possess a low-complexity N-terminus (residues 1--59), and a 'middle' domain (residues 367--707), also containing a low-complexity region (residues 396--553). Only the catalytic domain is represented in the available (bacterial) OGA structures, yet any of the additional hOGA domains could contribute to substrate recognition/specificity.

![Structure of *Og*OGA and similarity to other OGAs\
(**A**) Domain architecture of human OGA. Predicted ordered domains are shown as coloured boxes (cyan, catalytic domain; purple, stalk domain; orange, HAT domain), predicted disordered regions are indicated by red wavy lines. (**B**) Sequence alignment of *Og*OGA and hOGA. Secondary-structure elements from the *Og*OGA structure are shown (red, α-helices; blue, β-strands; yellow, 3~10~-helices), broken lines denote residues disordered in apo-*Og*OGA. The proposed domains are indicated by boxes coloured as in (**A**). (**C**) Cartoon view of the *Og*OGA apo structure and domains 2 and 3 of *Cp*NagJ. (**D**) Surface view of *Og*OGA shaded by sequence conservation among metazoan OGAs (light blue) and metazoan OGAs+*Og*OGA (dark blue). The PUGNAc (green) complex is shown with additional ordered loops taken from the apo-structure. (**E**) Active sites of the *Og*OGA--PUGNAc and *Cp*NagJ--GlcNAcstatin complexes. The ligands are represented as sticks with green carbons, an unbiased *F*~o~−*F*~c~;ϕ~c~ map (2.3 σ) is shown for PUGNAc. Hydrogen bonds are drawn as black broken lines. Hydrogen bonds to/from protein backbone amides are shown as originating from the Cα. Active-site residues in *Og*OGA are labelled in black, alongside the equivalent hOGA residues in blue.](bic654i002){#F2}

In the absence of a hOGA structure to guide our substrate-specificity studies, we aimed to identify new bacterial OGAs with improved sequence identity and extending to beyond just the catalytic domain. A BLAST search identified a predicted protein from *O. granulosus* (*Og*OGA) that not only shows improved sequence identity (37%) with the hOGA catalytic domain without any alignment gaps ([Figure 2](#F2){ref-type="fig"}B), but also, intriguingly, possesses a 200-residue C-terminal domain that shares approx. 20% identity with the hOGA middle domain ([Figures 2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}B). An *Og*OGA structure would reveal the position of this domain with respect to the active site and serve as a guide to identifying residues or domains involved in glycoprotein substrate recognition.

To investigate the possible OGA activity of *Og*OGA, the gene was cloned from genomic DNA and expressed in *E. coli*. The enzyme shows OGA activity with *p*NP-GlcNAc (*K*~m~=8.5±0.6 mM, *k*~cat~=24.0±1.0 s^−1^) and 4MU-GlcNAc (*K*~m~=2.9±0.2 mM, *k*~cat~=8.2±0.3 s^−1^), with a pH optimum of 7.4--7.6 (see Supplementary Figure S2B at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>). *Og*OGA is sensitive to the commonly used OGA inhibitors PUGNAc (IC~50~=11 μM) and GlcNAcstatin G \[[@B29a]\] (IC~50~=780 nM). *Og*OGA was also able to quantitatively deglycosylate a glycopentapeptide, Val-Ala-His-Ser-(β-*O*-GlcNAc)-Gly-Ala, derived from the reported hOGA *O*-GlcNAc site \[[@B4]\], as detected by LC--MS ([Figure 1](#F1){ref-type="fig"}C and Supplementary Figure S2).

*Og*OGA possesses a conserved peptide-binding groove and 'stalk'
----------------------------------------------------------------

We next explored the structural similarities of *Og*OGA with hOGA to allow exploitation of *Og*OGA as a structural guide for hOGA mutagenesis studies. *Og*OGA was crystallized and its structure solved, including a complex with PUGNAc (see Supplementary Table S1). The *Og*OGA structure reveals an N-terminal TIM barrel domain and a C-terminal α-helical domain ([Figures 2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}C). The *Og*OGA catalytic domain is similar to that of *Cp*NagJ (*Clostridium perfringens* NagJ) \[RMSD (root mean square deviation)=1.5 Å (1 Å=0.1 nm) for 254 C~α~s; [Figure 2](#F2){ref-type="fig"}C\]. The α4--β5, β3--α3, β4--α4 and β5--α5 loops are of different lengths and/or adopt different conformations. Strikingly, sequence alignments show that these loops match hOGA, but not *Cp*NagJ, in length and conservation ([Figure 2](#F2){ref-type="fig"}B). The C-terminal domain, hereafter referred to as the stalk domain, possesses good sequence similarity with hOGA ([Figure 2](#F2){ref-type="fig"}B) and contains a core four-helical bundle ([Figure 2](#F2){ref-type="fig"}C). Unexpectedly, this domain is structurally similar to the third domain of *Cp*NagJ (RMSD=1.9 Å for 110 C~α~s, yet \<10% sequence identity; [Figure 2](#F2){ref-type="fig"}C), although the loops connecting the helices differ in length and conformation. In particular, the α10--α11 loop is nine residues longer in *Cp*NagJ compared with *Og*OGA (and, by alignment, hOGA; [Figure 2](#F2){ref-type="fig"}B), reaching into the *Cp*NagJ active site, which is impossible in *Og*OGA (and thus unlikely in hOGA). Similarly, the *Og*OGA structure suggests structural homology between the stalk domain of *Bacteroides thetaiotaomicron* OGA \[[@B20]\] and hOGA (see Supplementary Figure S3 at <http://www.BiochemJ.org/bj/432/bj4320001add.htm>).

The *Og*OGA active site is formed by the TIM barrel β--α loops ([Figure 2](#F2){ref-type="fig"}C), with the catalytic loop residues Asp^115^/Asp^116^ on β4--α4 conserved with hOGA, compatible with the observed OGA activity ([Figure 2](#F2){ref-type="fig"}C). This loop does not fully engage with the PUGNAc inhibitor, presumably related to the disordered phenylcarbamate group. Ligand-induced conformational changes in the β4--α4 loop have also been observed for *Cp*NagJ \[[@B30]\]. Upon PUGNAc binding to *Og*OGA, the β7--η1 loop shifts by up to 4.7 Å exposing the GlcNAc-binding site, associated with small displacements of the neighbouring β8--α8 and β1--α1 loops. Residues hydrogen-bonding with the sugar hydroxy groups (Gly^8^, Tyr^160^, Asp^226^ and Asn^254^) or the *N*-acetyl moiety (Asn^221^) are conserved in hOGA ([Figures 2](#F2){ref-type="fig"}B and [2](#F2){ref-type="fig"}E). Similarly, the residues that show van der Waals/stacking interactions with the sugar and the *N*-acetyl group (Tyr^10^, Tyr^160^ and Trp^219^) are conserved in hOGA. Strikingly, the surface around the active site, together with the stalk domain, forms a groove lined by side chains that are highly conserved/identical between *Og*OGA and hOGA and also among metazoan OGAs ([Figure 2](#F2){ref-type="fig"}D).

Residues lining the conserved binding groove are required for hOGA--substrate interactions
------------------------------------------------------------------------------------------

We next tested the hypothesis that the conserved groove represents the binding site for *O*-GlcNAc glycoprotein substrates by expressing GST-fusions of 20 individual hOGA point mutants of residues lining the groove ([Figures 2](#F2){ref-type="fig"}B and [2](#F2){ref-type="fig"}D). To control for effects on protein folding and/or catalysis rather than protein substrate binding, we measured 4MU-GlcNAc hydrolysis by these mutants ([Figure 3](#F3){ref-type="fig"}A). Mutations affecting 4MU-GlcNAc hydrolysis are mostly located close to the sugar/catalytic machinery (Tyr^69^) or occupy positions shown to undergo a conformational change upon inhibitor binding (Tyr^286^ and Asp^287^ in the β7--η1 loop) ([Figure 2](#F2){ref-type="fig"}). Strikingly, de-*O*-GlcNAcylation assays with the TAB1, FoxO1 and CREB glycoprotein substrates identified mutants of residues some distance from the active site (I176L, S190A, S190Q, T217A, E218S, F223S and K289A) with reduced activity against one or more of the protein substrates, yet unimpaired 4MU-GlcNAc hydrolysis ([Figure 3](#F3){ref-type="fig"}).

![Activity of hOGA groove mutants\
Twenty individual mutants of hOGA were generated based on the structural information obtained from *Og*OGA. (**A**) To evaluate the structural integrity of the hOGA mutants, the catalytic efficiency of 4MU-GlcNAc turnover was determined and compared with the wild-type (*k*~cat~/*K*~m~=7000 M^−1^·s^−1^) and the catalytically impaired D175N mutant (negative control). hOGA mutants were also incubated with *O*-GlcNAc substrate proteins TAB1, FoxO1 and CREB, and deglycosylation was observed by Western blotting. (**B**) Visualization of the correlation between the mutants\' ability to hydrolyse the pseudosubstrate 4MU-GlcNAc and glycoprotein substrates. Catalytically impaired mutants (*k*~cat~/*K*~m~ for 4MU-GlcNAc ≤50% of wild-type) locate in the areas shaded in red. Mutants unaffected in both 4MU-GlcNAc turnover and protein deglycosylation (cut-off 10% reduction of wild-type activity) are shown in the blue areas. Mutations reducing OGA activity on protein substrates only are depicted in the yellow areas. Location of the mutations is shown on the surface around the active site of *Og*OGA (coloured by domain, see [Figure 2](#F2){ref-type="fig"}A). The mutated amino acids are shaded according to correlation plots, thus amino acids affecting protein substrate recognition are highlighted in yellow.](bic654i003){#F3}

Conclusions
-----------

Since its discovery more than three decades ago, it has become clear that *O*-GlcNAc is an important post-translational modification found on hundreds of intracellular proteins and plays a role in signalling pathways. However, it is not clear what determines specificity in the targeting and cycling of *O*-GlcNAc on these proteins. We have investigated whether OGA specifically recognizes the peptide component of its glycoprotein substrates. Our findings show that, by similarity to the structurally related bacterial *Og*OGA, hOGA possesses a putative substrate-binding groove that is highly conserved within metazoan OGAs, in addition to a stalk domain in close proximity to the active site. Indeed, mutations targeting this groove identified residues that are not required for hydrolysis of the 4MU-GlcNAc pseudosubstrate, but affected hydrolysis of glycoprotein substrates. Although a limited set of glycoprotein substrates (TAB1, FoxO1 and CREB) and peptides (derived from TAB1 and hOGA itself) was tested, these mutational studies hinted at differential substrate recognition. The differences between the residues required for the turnover of these substrates may reflect differences in the molecular environment of the *O*-GlcNAc site(s) on these proteins/peptides, and could tune *O*-GlcNAc cycling rates. Together, the results of the present study constitute the first evidence for specific interactions between hOGA and its substrate proteins beyond the sugar moiety, and may form the basis of an improved understanding of the enzyme\'s substrate specificity and the functional implications thereof.

Online data
===========

###### Supplementary data

AUTHOR CONTRIBUTION
===================

The scientific hypothesis was devised by Marianne Schimpl, Alexander Schüttelkopf and Daan van Aalten. The experimental design was by Marianne Schimpl, Alexander Schüttelkopf, Vladimir Borodkin and Daan van Aalten. Experimentation was by Marianne Schimpl, Alexander Schüttelkopf and Vladimir Borodkin. Interpretation of results was by Marianne Schimpl, Alexander Schüttelkopf and Daan van Aalten who also wrote the paper.

ACKNOWLEDGEMENTS
================

We thank Sharon Shepherd for assistance with protein production, Lindsey Gray for assistance with peptide synthesis, Adel Ibrahim for help with molecular cloning, and the European Synchrotron Radiation Facility, Grenoble, for time on BM14, ID23-2 and ID14-1.

FUNDING
=======

This work was supported by a Wellcome Trust Senior Research Fellowship to D.M.F.v.A. and a Wellcome Trust Ph.D. Studentship to M.S.

[^1]: ^1^These authors contributed equally to this work

[^2]: Structures have been deposited in the PDB under accession codes 2XSA and 2XSB.
